The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is ...important. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges. No further updates to the previous existing recommendations were made in this latest version.
This updated (fifth) version contains 16 new recommendations for the rehabilitation of adults with post COVID-19 condition (see Chapter 24)
This updated (fourth) version contains three new recommendations regarding hospitalized patients with severe or critical COVID-19
more
Ce document d'orientation est destiné aux cliniciens qui s'occupent de patients atteints de COVID-19 à toutes les phases de leur maladie (c'est-à-dire du dépistage à la sortie de l'hôpital). Cette mise à jour a été étendue pour répondre aux besoins des cliniciens de première ligne et fa...vorise une approche multidisciplinaire des soins aux patients atteints de COVID-19, y compris ceux qui présentent une maladie légère, modérée, grave et critique. Les sections suivantes sont entièrement nouvelles : parcours de soins COVID-19, traitement des infections aiguës et chroniques, gestion des manifestations neurologiques et mentales, maladies non transmissibles, réadaptation, soins palliatifs, principes éthiques et déclaration du décès ; les chapitres précédents ont également été considérablement étoffés.
more
Journal of Palliative Medicine Volume 21, Number 10, 2018
DOI: 10.1089/jpm.2018.0248ad
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ...with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
Versión abreviada. En esta versión abreviada de las Directrices de práctica clínica basadas en la evidencia para el seguimiento de recién nacidos en riesgo se brindan recomendaciones para la atención de recién nacidos hasta los 2 años y corresponden a la primera fase de su seguimiento. Las r...ecomendaciones están dirigidas a todos los funcionarios del sector de la salud responsables de la atención primaria de estos recién nacidos: médicos generales, médicos de familia, pediatras, neonatólogos, oftalmólogos pediatras, otorrinolaringólogos pediatras, profesionales de enfermería, especialistas en otros campos y personal multidisciplinario que interviene en el proceso de atención
more
Временные методические рекомендации, представленные в документе, базируются на материалах по медицинской реабилитации пациентов с COVID-19 на различных этапах оказ...ания специализированной медицинской
помощи, опубликованных специалистами ВОЗ, анализе отчётов клиник, осуществляющие медицинскую реабилитацию пациентов с COVID-19 в данный момент, а также на результатах клинических исследований, проведенных ранее и посвященных реабилитации пациентов с ПИТ-синдромом (синдромом последствий интенсивной терапии) и ОРДС
взрослых некоронавирусной этиологии, нормативно-правовых документах Минздрава России и Роспотребнадзора.
more
Nota INformatIva Nº 13/2020 - SE/GaB/SE/mS
September 2020
ESTA NOTA INFORMATIVA SUBSTITUI A NOTA INFORMATIVA Nº 11/2020-SE/GAB/SE/MS, DE 15 DE JUNHO DE 2020, QUE SUBSTITUIU A NOTA INFORMATIVANº 9/2020-SE/GAB/SE/MS, DE 20 DE MAIO DE 2020
Recommendations for health care professionals – the experience from Latvia
A guide to support implementation of health service Quality Improvement activities in Ethiopian health facilities
Ethiopia has seen high economic growth over the last decade, but remains a poor country with a high burden of disease. It has made considerable health gains in recent years, mainly by having health policies that focus on extending primary healthcare, using health extension workers. It... has made good use of existing resources,but has a low health expenditure (of around US$21 per capita, and totalling 4per centof GDP). It has a federal system with devolved healthcare financing, whereby block grants are allocated to sectors at regional and woreda(district) level. The challenge now,with the epidemiological transition (and a sense that the ‘low-hanging fruits’have already been gathered in relation to public health), is how Ethiopia, still poor, continuesto invest in health improvements?Human resources for health (HRH) are a critical pillar within any health system –the health staff combine inputs to provide the services, thus affecting how all other resources are used, and they make frontline (and back-office) decisions thatare importantdeterminants of servicequality,effectiveness and equity. HRH is usually the most resource-intensive element within the health system –commonly absorbing 50–70per centof public expenditure onhealth, although the proportions are very varied by individual countries and across regions. As they are commonly part of the public administration, reforms to HRH are also part of a complex political economy in most countries.Assessing value for money (VfM) in relation to HRH is correspondingly complex;across the value chain, manyfactors influence the conversion of inputs into outputs and outcomes (see Figure 1).A more detailed description of the HRH value chain can be found in Annex1.
more